Tag

Ultimovacs

Carlos de Sousa

Ultimovacs strengthens IP portfolio

August 24, 2022

Ultimovacs has announced that the …

Carlos de Sousa

Ultimovacs receives Notice of Allowance on US Patent

April 25, 2022

Ultimovacs has received a Notice …

Ultimovacs progresses to last cohort in Phase I trial

February 7, 2022

Ultimovacs has completed treatment of …

Ultimovacs lab

First patient enrolled in Ultimovacs’ DOVACC trial

December 15, 2021

Ultimovacs has announced that the …

Carlos de Sousa

Ultimovacs granted Orphan Drug Designation by FDA

December 3, 2021

Ultimovacs has announced that the …

Gustav Gaudernack

Ultimovacs announces new data

November 16, 2021

Ultimovacs has announced data showing …

Ultimovacs to launch Phase II combination trial

October 27, 2021

Ultimovacs’s universal cancer vaccine, UV1, …

Ultimovacs lab

Ultimovacs receives dual FDA Fast Track designation

October 22, 2021

Ultimovacs has announced that its …

Carlos de Sousa

Ultimovacs announces positive follow-up data

October 18, 2021

Ultimovacs has announced continuing positive …

Ultimovacs lab

Ultimovacs begins dosing of 2nd cohort in Phase I TENDU study

October 4, 2021

Ultimovacs has started dosing of …

Interview: Jens Bjørheim, Chief Medical Officer, Ultimovacs

September 17, 2021

The company’s universal cancer vaccine, …

Ultimovacs lab

Further positive trial results from Ultimovacs

August 12, 2021

Ultimovacs has announced positive results …

Jens Bjorheim

First patient enrolled in Ultimovacs trial

August 9, 2021

Ultimovacs has announced that the …

New promising findings about Ultimovacs’ cancer vaccine

May 24, 2021

Ultimovacs has announced that its …

Sara Mangsbo Photo Mikael Wallerstedt

First patient treated in Ultimovacs TENDU study

February 18, 2021

Ultimovacs has announced the treatment …

#D illustration of ovarian cancer

Ultimovacs announces Phase II collaboration study in ovarian cancer

January 14, 2021

Ultimovacs will participate in the …

1
2